Romanian Society of Pharmaceutical Sciences
 

« Back to Farmacia Journal 3/2018

NEW APPROACHES AND PERSPECTIVES FOR THE PHARMACOLOGICAL TREATMENT OF ARTERIAL HYPERTENSION

CAMELIA CRISTINA DIACONU 1#, CRISTINA MANUELA DRĂGOI 2#*, OVIDIU GABRIEL BRATU 3#, TIBERIU PAUL NEAGU 1#, ANCA PANTEA STOIAN 4#, PAVEL CĂLIN COBELSCHI 5#, ALINA CRENGUȚA NICOLAE 2#, MIHAELA ADELA IANCU 6#, RĂZVAN HAINĂROȘIE 7#, ANA MARIA ALEXANDRA STĂNESCU 8#, BOGDAN SOCEA 9#

1.“Carol Davila” University of Medicine and Pharmacy, Clinical Emergency Hospital of Bucharest, Romania
2 .“Carol Davila” University of Medicine and Pharmacy, Faculty of Pharmacy, Bucharest, Romania
3 .“Carol Davila” University of Medicine and Pharmacy, Emergency Central Military Hospital, Bucharest, Romania
4 .“Carol Davila” University of Medicine and Pharmacy, “N. C. Paulescu” Institute, Bucharest, Romania
5 .Transilvania University, Faculty of Medicine, Brașov, Romania
6 .“Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania
7 .“Carol Davila” University of Medicine and Pharmacy, “Prof. Dr. Dorin Hociotă” Institute of Phonoaudiology and
Functional ENT Surgery, Bucharest, Romania
8 .“Carol Davila” University of Medicine and Pharmacy, Elias Hospital, Bucharest, Romania
9 .“Carol Davila” University of Medicine and Pharmacy, Clinical Emergency Hospital “Sf. Pantelimon”, Bucharest, Romania

Download Full Article PDF

Arterial hypertension is one of the most common cardiovascular diseases worldwide. Despite the availability of various antihypertensive drug classes, a high percentage of hypertensive population have uncontrolled blood pressure values. Due to the very high prevalence of the disease, there is a major interest for developing more effective antihypertensive drugs, with a better safety profile and impact on the short and long-term cardiovascular outcomes of hypertensive patients. During the last years, new drugs have been developed to control the high blood pressure: a novel mineralocorticoid receptor antagonist, inhibitors of vasopeptidases, aldosterone synthase and soluble epoxide hydrolase, agonists of natriuretic peptide A and vasoactive intestinal peptide receptor 2, inhibitors of aminopeptidase A, dopamine beta-hydroxylase inhibitors, intestinal Na+/H+ exchanger 3 inhibitors, agonists of components of the angiotensin-converting enzyme 2/angiotensin(1-7)/Mas receptor axis, vaccines against angiotensin II and its type 1 receptor. These new drug classes address different pathophysiological mechanisms involved in the appearance of arterial hypertension. This review focuses on new drug development for the treatment of arterial hypertension.